Evidence map›Paper›PMID 37306927›Full record

ArticleGenes & genomics2023

Postoperative circulating tumor DNA detection and CBLB mutations are prognostic biomarkers for gastric cancer.

Hekai Zhou, Houcong Liu, Jun Li, Jidong Wang, Xiaohong Fu, Yingqiang Li, Shaolong Mao, Jihui Du

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hekai Zhou *Research Center for Clinical and Translational Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, and the 6th Affiliated Hospital of Shenzhen University Medical School, Guangdong, 518052, Shenzhen, China.
Houcong Liu *Research Center for Clinical and Translational Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, and the 6th Affiliated Hospital of Shenzhen University Medical School, Guangdong, 518052, Shenzhen, China.
Jun Li *HaploX Biotechnology Co., Ltd., Shenzhen, 518057, Guangdong, China.
Jidong WangResearch Center for Clinical and Translational Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, and the 6th Affiliated Hospital of Shenzhen University Medical School, Guangdong, 518052, Shenzhen, China.
Xiaohong FuDepartment of Oncology, Huazhong University of Science and Technology Union Shenzhen Hospital, and the 6th Affiliated Hospital of Shenzhen University Medical School, Guangdong, 518052, Shenzhen, China.
Yingqiang LiHaploX Biotechnology Co., Ltd., Shenzhen, 518057, Guangdong, China.
Shaolong MaoHaploX Biotechnology Co., Ltd., Shenzhen, 518057, Guangdong, China.
Jihui DuResearch Center for Clinical and Translational Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, and the 6th Affiliated Hospital of Shenzhen University Medical School, Guangdong, 518052, Shenzhen, China. jihuidu@email.szu.edu.cn.ORCID 0000-0002-8688-8076
Shenzhen University · CNShenzhen Bioeasy Biotechnology (China) · CN

Funding

Research Funds of the Science, Technology and Innovation Commission of Shenzhen No. JCYJ20190809105001757Shenzhen Healthcare Research Project No. SZLY20180131
6 · The paper itself

Abstract

backgroundSeveral studies have demonstrated that circulating tumor DNA (ctDNA) can be used to predict the postoperative recurrence of several cancers. However, there are few studies on the use of ctDNA as a prognosis tool for gastric cancer (GC) patients.

objectiveThis study aims to determine whether ctDNA could be used as a prognostic biomarker in GC patients through multigene-panel sequencing.

methodsUsing next-generation sequencing (NGS) Multigene Panels, the mutational signatures associated with the prognosis of GC patients were identified. We calculated the survival probability with Kaplan-Meier and used the Log-rank test to compare survival curves between ctDNA-positive and ctDNA-negative groups. Potential application of radiology combined with tumor plasma biomarker analysis of ctDNA in GC patients was carried out.

resultsDisease progression is more likely in ctDNA-positive patients as characterized clinically by a generally higher T stage and a poorer therapeutic response (P < 0.05). ctDNA-positive patients also had worse overall-survival (OS: P = 0.203) and progression-free survival (PFS: P = 0.037). The combined analysis of ctDNA, radiological, and serum biomarkers in four patients indicated that ctDNA monitoring can be a good complement to radiological and plasma tumor markers for GC patients. Kaplan-Meier analysis using a cohort of GC patients in the TCGA database showed that patients with CBLB mutations had shorter OS and PFS than wild-type patients (OS: P = 0.0036; PFS: P = 0.0027).

conclusionsThis study confirmed the utility and feasibility of ctDNA in the prognosis monitoring of gastric cancer.

Indexed as

Circulating Tumor DNALung NeoplasmsStomach NeoplasmsAdaptor Proteins, Signal TransducingHumansMutationPrognosisProto-Oncogene Proteins c-cblAdaptor Proteins, Signal TransducingCBLB protein, humanCirculating Tumor DNAProto-Oncogene Proteins c-cblBiomarkerCBLBctDNAGastric cancerPrognosis

Identifiers

PMID37306927
PMCPMC10349697
OpenAlexW4380290875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.